Lv1
34 积分 2024-03-05 加入
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma
1天前
待确认
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
6天前
已完结
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
18天前
已完结
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
18天前
已完结
Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B
18天前
已完结
Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma
19天前
已完结
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1个月前
已完结
Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities
1个月前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC
4个月前
已完结
皖公网安备34019202002308
